LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
• Lipid-lowering therapies, particularly statins, are crucial in managing dyslipidemia and reducing CVD risk.
• Achieving specific low-density lipoprotein cholesterol (LDL-C) targets is a cornerstone of effective CVD prevention.

Purpose of the Study:

• To compare the proportion of patients achieving LDL-C goals (2.5 or 2.0 mmol/l) with simvastatin versus atorvastatin.
• To investigate the relationship between lipoprotein components and CVD outcomes in patients reaching target LDL-C levels.

Main Methods:

• Analysis of data from the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study.
• Comparison of LDL-C goal attainment rates between simvastatin (20/40 mg) and atorvastatin (80 mg) groups.
• Cox regression models to assess the predictive value of lipoprotein components (apoB/A1 ratio) for CVD events.

Main Results:

• Atorvastatin (80 mg) resulted in significantly higher LDL-C goal attainment (2.5 mmol/l: 80%; 2.0 mmol/l: 52%) compared to simvastatin (2.5 mmol/l: 40%; 2.0 mmol/l: 12%).
• Patients achieving the lower LDL-C goal (<2.0 mmol/l) had a 16% lower risk of CVD events (HR 1.16; p=0.023) compared to those reaching 2.0-2.5 mmol/l.
• In patients reaching 2.0 mmol/l LDL-C, an increased apoB/A1 ratio was associated with a higher risk of CVD (HR 1.14; p=0.004).

Conclusions:

• Atorvastatin is more effective than simvastatin in achieving LDL-C goals in high-risk patients.
• Attaining lower LDL-C levels (<2.0 mmol/l) is associated with significantly reduced CVD events.
• The apoB/A1 ratio provides additional prognostic information for CVD risk beyond LDL-C levels, especially in patients at goal.